Arch Therapeutics to Provide Corporate Updates at Upcoming Industry and Investment Conferences

FRAMINGHAM, Mass., Sept. 20, 2017 -- Terrence Norchi, MD, CEO of Arch Therapeutics, Inc. (OTCQB:ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, will present at the 17^th Annual Biotech in Europe Forum for Global Partnering & Investment in Basel, Switzerland and The MicroCap Conference in New York City.

Dr. Norchi is scheduled to present at the 17th Annual Biotech in Europe Forum on Tuesday, September 26, 2017 at 4:05 PM local time (GMT +2) at the Congress Center Basel. For more information about this conference, please visit: http://www.sachsforum.com.

Dr. Norchi is also scheduled to provide a company update at The MicroCap Conference on October 5, 2017 at The Essex House, New York, NY. For more information about the conference or to schedule a meeting, please click the following link: http://microcapconf.com. The presentations will be available for download at: http://ir.archtherapeutics.com.

About Arch Therapeutics, Inc. 
Arch Therapeutics, Inc. is a biotechnology company developing a novel approach to stop bleeding (hemostasis), control leaking (sealant) and manage wounds during surgery, trauma and interventional care. Arch is developing products based on an innovative self-assembling barrier technology platform with the goal of making care faster and safer for patients. Arch's development stage product candidates include the AC5™ Topical Gel and the AC5™ Surgical Hemostatic Device.

Notice Regarding Forward-Looking Statements 
This news release contains "forward-looking statements" as that term is defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, references to novel technologies and methods, our business and product development plans and projections, or market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with developing new products or technologies and operating as a development stage company, our ability to retain important members of our management team and attract other qualified personnel, our ability to raise the additional funding we will need to continue to pursue our business and product development plans, our ability to obtain required regulatory approvals, our ability to produce commercial quantities of our products within projected timeframes, our ability to develop and commercialize products based on our technology platform, and market conditions. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the reports and other documents we file with the SEC, available at www.sec.gov.

Contact
ARTH Investor Relations
Toll Free: +1-855-340-ARTH (2784) (US and Canada)
Email: [email protected] 
Website: www.archtherapeutics.com

or

Richard Davis
Chief Financial Officer
Arch Therapeutics, Inc.
Phone: 617-431-2308
Email: [email protected]
Website: www.archtherapeutics.com